TFA salt peptides: counterions, net peptide content and assays

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

A TFA salt is a peptide whose positive charges are balanced by trifluoroacetate, the negatively charged ion left behind by the trifluoroacetic acid (TFA) used to cleave and purify synthetic peptides. The counterion adds weight that is not peptide: a 2025 study measured trifluoroacetate at up to 35% of the total weight of the peptide salts it examined. It can also matter in experiments, because a 2026 mouse study reported that trifluoroacetate itself is biologically active. Neither a high-performance liquid chromatography (HPLC) purity figure nor a mass spectrum reports the counterion, so it needs its own measurement.

What is a peptide counterion?

Peptides carry electrical charges. The free amino group at the N-terminus and the side chains of lysine, arginine and histidine can carry a positive charge, while aspartate and glutamate side chains can carry a negative one. A solid peptide salt must be electrically neutral overall, so each net positive charge is paired with a negative ion. That negative ion is the counterion.

A 2020 review in Pharmaceuticals by Sikora and colleagues notes that, because amino acid side chains can be basic, acidic or neutral, peptide drugs often exist as salts with different counterions, and it examines how the counterion affects structure, physicochemical properties and formulation. Three counterions come up most often: trifluoroacetate (the TFA salt), acetate and chloride, the last usually called the hydrochloride or HCl salt.

The European Medicines Agency (EMA) guideline on synthetic peptides, legally effective from 1 June 2026, makes the counterion part of the substance’s description. It asks for the counterion to be stated where relevant, along with whether it is present in a fixed (stoichiometric) ratio. It notes that acetate is usually used for synthetic peptide medicines, that trifluoroacetate and chloride are also possible, and that the type of counterion can affect a peptide’s biological and physicochemical properties.

Why are synthetic peptides often TFA salts?

Most synthetic peptides are made by solid-phase peptide synthesis (SPPS), building the chain one residue at a time on a resin bead. Trifluoroacetic acid is used twice:

• Cleavage. Concentrated trifluoroacetic acid releases the finished peptide from the resin and removes side-chain protecting groups.
• Purification. Reversed-phase HPLC mobile phases commonly contain dilute trifluoroacetic acid as an ion-pairing reagent. A methods chapter by Mant and colleagues explains that these mobile phases are preferred because they are volatile and separate complex peptide mixtures well.

Freeze-drying removes free acid, but trifluoroacetate held as a counterion on the peptide’s positive groups stays behind. As the Sikora review puts it, cleavage and purification are performed using TFA, so cationic peptides are obtained as trifluoroacetate salts. A 2025 study in Pharmaceuticals by Erckes and colleagues describes the same chain of events, and a 2014 review of impurities in peptide medicines by D’Hondt and colleagues lists unwanted trifluoroacetate counterions among the impurities linked to synthesis. Our guide to lyophilised peptides explains the freeze-drying step.

TFA vs acetate vs HCl salts: what is the difference?

No salt form should be assumed to be inert. In the 2025 Erckes study, passive permeability across liposome membranes, measured in vitro, varied with both the peptide sequence and the salt form.

Net peptide content vs gross weight

The gross weight is the mass of powder in the vial. It includes the peptide, its counterions, residual water and any other non-peptide material. The net peptide content is the share of that mass that is actually peptide. The two can differ widely.

In the 2025 Erckes study, trifluoroacetate reached up to 35% of the total weight of the peptide salts tested, and chloride up to 10%. The difference reflects both the number of positive charges on each peptide and the mass of the counterion: trifluoroacetate is much heavier than chloride.

Illustrative arithmetic, not data for any product: a peptide of 1,500 daltons (Da) with three positive charges, each paired with a trifluoroacetate ion of about 113 Da, carries about 340 Da of counterion. The peptide is then roughly 82% of the salt’s mass before any water is counted.

This is why HPLC purity and net peptide content are different numbers. An HPLC area percentage compares peptide-related peaks with each other; it does not see water or counterions. A sample can show high chromatographic purity and still contain substantially less peptide than its gross weight suggests. The EMA guideline reflects this: it expresses assay limits on a counterion-free, anhydrous basis, and defines the strength of a finished medicine by the mass of peptide base, not including salt or counterion.

Metrology laboratories draw the same line when they assign values to peptide reference materials. In CCQM-K115, an international key comparison of peptide purity reported by the Bureau International des Poids et Mesures (BIPM) in 2017, the mass-balance calculation for a high-purity synthetic human C-peptide started from the whole material and subtracted peptide-related impurities, water, trifluoroacetate, volatile organic solvents, cations and other anions. The agreed reference value for the C-peptide itself was 801.8 mg/g, about 80% of the material’s mass. That is one carefully characterised material, not a typical figure for research peptides, but it shows how far gross weight and peptide content can sit apart.

The EMA guideline lists methods for measuring content, including chromatographic assay against a reference standard, amino acid analysis, elemental or Kjeldahl nitrogen analysis and quantitative nuclear magnetic resonance (NMR) spectroscopy, known as qNMR. A 2018 review in TrAC Trends in Analytical Chemistry by Josephs and colleagues compared the main routes for assigning a peptide’s purity as a mass fraction, using angiotensin I as a model: a full mass balance, amino acid analysis corrected for peptide impurities, elemental analysis and qNMR. For the counterion itself, the Sikora review describes ion chromatography as the technique of first choice. The 2025 Erckes study used Fourier-transform infrared spectroscopy (FT-IR), fluorine-19 NMR and HPLC with an evaporative light-scattering detector. See 99% purity: what does that number actually tell you? for more on area percentages.

What the research shows about TFA in experiments

Concern about trifluoroacetate in biological work is not new, and the evidence comes from cell and animal models.

• Cell culture, 1999. A study in the American Journal of Physiology by Cornish and colleagues described trifluoroacetate as a contaminant in purified proteins and reported that it reduced the proliferation of cultured osteoblasts and chondrocytes (bone- and cartilage-forming cells). When the same peptides were compared as trifluoroacetate and hydrochloride salts, proliferation was consistently lower with the trifluoroacetate salts. The authors suggested converting purified peptides to hydrochloride or similar salts before testing their biological activity. In vitro.
• Review, 2020. The Sikora review summarises reports that TFA can interfere with physicochemical characterisation and can affect mammalian cells, sometimes inhibiting proliferation. It also cites a report of trifluoroacetate stimulating the growth of glioma cells. The direction of the effect depends on the system. Review.
• Literature summary, 2025. The introduction to the Erckes study summarises in vitro and in vivo reports that residual trifluoroacetate has both increased and inhibited cell proliferation, increased cell and liver toxicity and led to greater activation of antibody responses. Summary of earlier studies.
• Mouse and cell studies, 2026. A study in Nature Communications by Tang and colleagues reported that trifluoroacetate induced peroxisome proliferation and metabolic changes in three mouse strains and in cultured liver cells. The effects were seen with trifluoroacetate alone and as the counterion of several unrelated short synthetic peptides. The authors reported changes in plasma lipids and in atherosclerotic lesion development in one mouse model, and mechanistic evidence that trifluoroacetate binds peroxisome proliferator-activated receptor alpha (PPAR-alpha). Animal and in vitro.

The honest boundary: these findings show that trifluoroacetate is not an inert bystander in the systems tested. They do not show that every peptide experiment is affected, or by how much. Whether it matters depends on the assay, the readout and how much counterion reaches the system.

Trifluoroacetic acid can also matter during analysis. A 2026 study of liquid chromatography–mass spectrometry (LC-MS) methods for therapeutic proteins in Pharmaceuticals listed reduced TFA exposure among its control strategies for artificial methionine oxidation. Our article on peptide oxidation covers that problem.

Can TFA be removed or exchanged?

Yes, though no method is free of trade-offs. The 2025 Erckes study lists the techniques that have been described: anion-exchange columns, reversed-phase HPLC with varying counterion concentrations, repeated deprotonation and reprotonation, and treatment with a stronger acid such as hydrochloric acid followed by freeze-drying. Two routes come up most often:

• Exchange to chloride by freeze-drying the peptide from dilute hydrochloric acid, which the Erckes authors describe as probably the most convenient and widely adopted approach. Their study compared several acid strengths, identified an optimal condition for its peptides and saw no effect on purity at any of the strengths tested.
• Exchange to acetate. The Sikora review notes that exchange to acetate uses distinctly milder conditions than exchange with hydrochloric acid, which runs below pH 1.

After any exchange, the residual trifluoroacetate and the new counterion content need to be measured again, because the salt form on the label is only as good as the test behind it.

How to account for counterions in a study

• Record the salt form stated on the batch laboratory report. If it is not stated, ask the supplier.
• State the basis for every amount: gross powder weight or net peptide content. Two papers using the same nominal amount may have used different quantities of peptide.
• Keep the salt form constant within a study. Changing batch or supplier can change the counterion even when the sequence is identical.
• Add a counterion-only control where the readout could plausibly respond to trifluoroacetate, such as proliferation, metabolism or membrane assays.
• Read purity and content separately. See HPLC vs mass spectrometry and How to read a peptide COA.

Thistle shows a batch laboratory report on each product page, and you can look up a batch on our batch report lookup.

Peptide counterion and TFA salt FAQs

What is a TFA salt peptide?

It is a peptide supplied with trifluoroacetate as the counterion balancing its positive charges. It is the usual form after standard solid-phase synthesis and HPLC purification.

What is the difference between TFA and acetate peptides?

The peptide sequence is the same; the counterion differs. Acetate is lighter and is the usual counterion for synthetic peptide medicines, while trifluoroacetate has been reported to be biologically active in cell and mouse studies.

Does TFA affect cell or animal experiments?

It can. Cell and mouse studies have reported effects of trifluoroacetate on its own, so for sensitive readouts a counterion-only control or a different salt form is worth considering.

What is net peptide content?

It is the proportion of the powder’s weight that is peptide, after excluding counterions, water and other non-peptide material. It is measured separately from HPLC purity, for example by amino acid analysis or quantitative NMR.

Can TFA be removed from a peptide?

It can be exchanged for chloride or acetate, but the result should be confirmed by measuring residual trifluoroacetate afterwards.

Sources

• Tang W, Black AS, Moench R, et al. Trifluoroacetate mediated reduction of atherosclerosis in mice. Nature Communications. 2026. Published 2 September 2026. Mouse models and cultured liver cells.
• Erckes V, Streuli A, Chamera Rendueles L, Krämer SD, Steuer C. Towards a consensus for the analysis and exchange of TFA as a counterion in synthetic peptides and its influence on membrane permeation. Pharmaceuticals. 2025;18(8):1163. In vitro analytical study.
• Sikora K, Jaśkiewicz M, Neubauer D, Migoń D, Kamysz W. The role of counter-ions in peptides: an overview. Pharmaceuticals. 2020;13(12):442. Review.
• Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. American Journal of Physiology – Endocrinology and Metabolism. 1999;277(5):E779–E783. Cell culture.
• European Medicines Agency. Guideline on the development and manufacture of synthetic peptides. EMA/CHMP/CVMP/QWP/367182/2025. Legally effective 1 June 2026. Medicinal-product guidance.
• Josephs RD, Li M, Song D, et al. CCQM-K115: key comparison study on peptide purity – synthetic human C-peptide. Final report. Bureau International des Poids et Mesures (BIPM). January 2017. International metrology comparison.
• Josephs RD, Stoppacher N, Daireaux A, et al. State-of-the-art and trends for the SI traceable value assignment of the purity of peptides using the model compound angiotensin I. TrAC Trends in Analytical Chemistry. 2018;101:108–119. Review.
• D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. Review.
• Mant CT, Chen Y, Yan Z, et al. HPLC analysis and purification of peptides. Methods in Molecular Biology. 2007;386:3–55. Methods chapter.
• Duan Y, Lanzillotti M, Riggs DL, et al. Artificial oxidation: a major challenge in implementing multi-attribute methods for therapeutic protein analysis. Pharmaceuticals. 2026;19(4):528.

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.